Organisation paid for research Program year 2025 Source: CMS Open Payments

Cincinnati Eye Institute

Neither a doctor nor a teaching hospital

Research payments

$3,858,576

498 payments

Through program year 2025, Cincinnati Eye Institute is reported as receiving $3,858,576 in research payments, across 498 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $241,232 156
2024 Research $128,955 63
2023 Research $59,598 27
2022 Research $676,359 54
2021 Research $1,108,470 74
2020 Research $1,063,850 76
2019 Research $580,112 48

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $2,796,567 160 payments
  2. Novartis Pharmaceuticals Corporation $409,455 7 payments
  3. Regeneron Pharmaceuticals, Inc. $306,696 179 payments
  4. Glaukos Corporation $188,427 70 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $78,886 28 payments
  6. Biogen, Inc. $22,506 4 payments
  7. Astellas Pharma Global Development $15,600 2 payments
  8. Dompe US, Inc. $11,424 5 payments
  9. Alcon Research LLC $9,880 9 payments
  10. AbbVie, Inc. $5,400 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. Study of the Port Delivery System With Ranibizumab in Patients With Diabetic MacUlar Edema $879,125 25 payments
  2. Port Delivery System for Ranibizumab $332,302 17 payments
  3. Va2 Phiii $291,240 20 payments
  4. A Two Year, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Diabetic MacUlar Edema $286,582 3 payments
  5. Port Delivery System of Ranibizumab Extension Study $269,778 14 payments
  6. Port Delivery System of Ranizibumab Extension Study $218,315 14 payments
  7. Va2 Phiii Yosemite $205,672 17 payments
  8. A Randomized, Double-Masked, Active-Controlled Phase 2/3 Study of the Efficacy and Safety of High-Dose Aflibercept in Patients With Diabetic Macular Edema $173,926 132 payments
  9. A Phase III Study to Evaluate Faricimab in Patients With Branch Retinal Vein Occlusion $124,923 7 payments
  10. Lucentis Fsv4 Lad Amd Ladder $123,438 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record